Oscient Pharmaceuticals' Board of Directors Names 25-Year Lilly Veteran John E. Voris to Board
Oscient Pharmaceuticals Corporation's Board of Directors has named John E. Voris as its newest member. Mr. Voris' years as an executive at Eli Lilly and Company, as well as his position as CEO at a leading medical software company have given him keen insight into successful strategies for building a healthcare enterprise.
Mr. Voris spent nearly three decades at Lilly, serving in a variety of leadership roles, including Executive Vice President of the Lilly subsidiary PCS Health Systems. He also served as the Executive Director of the Infectious Disease Business Unit and throughout his time at Lilly, gained experience in sales and marketing both in the U.S. and abroad. Most recently, Mr. Voris was the President and CEO during the start-up and development phases of Epocrates, Inc., a software company providing clinical information to healthcare professionals at the point of care. He continues his association with Epocrates as Chairman of the Board and also serves on the Board of Gentiae, a successful clinical research company. Mr. Voris is a graduate of the Kelley School of Business at Indiana University, where he earned both a bachelor's degree and an M.B.A.
Separately, Oscient's Board of Directors has announced the resignation of William J. Rutter, Ph.D. An original member of the Board of GeneSoft Pharmaceuticals, Dr. Rutter was instrumental in guiding Genesoft, and subsequently Oscient, through the complexities of a merger and a product launch.
Other news from the department people
These products might interest you
Limsophy by AAC Infotray
Optimise your laboratory processes with Limsophy LIMS
Seamless integration and process optimisation in laboratory data management
ERP-Software GUS-OS Suite by GUS
Holistic ERP solution for companies in the process industry
Integrate all departments for seamless collaboration
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
